What is a "food-derived bioactive technology" and a "functional food"?
It is becoming increasingly accepted by the scientific community that there are links between specific food groups and their capacity to help reduce the risk of certain diseases. For example, some compounds specifically found in broccoli have been shown to reduce the risk of some cancers. Consuming the actual food may be insufficient to maximise the health benefit due to a number of factors including: the quantity of the food that would need to be consumed; the frequency with which it would need to be consumed; and the way in which the food is prepared prior to consumption.

These health-promoting compounds can be extracted from the food source (called a food-derived bioactive technology) and reintroduced into consumer-friendly lifestyle products which are proven to maintain health (a functional food). Therefore, instead of eating four large servings of broccoli per week, the same benefit may be technically delivered via a 250ml orange juice drink containing the bioactive if consumed once per week.

How is Provexis differentiated from other companies in the market?
Provexis is an evidence-based business which means that we only develop food-derived bioactive technologies and functional food products that have been scientifically proven to deliver a health benefit. This is a different approach from those that promote functional food products in a more generic way with less scientific evidence. We believe that functional food products with strong scientific proof carrying health claims and endorsements will endure and prosper as this rapidly growing market matures.

Provexis is also differentiated with regard to our speed-to-market credentials and the fact that we can create shareholder value via a combination of technology licensing and own brand development.

What food-derived bioactive technologies are being developed by Provexis?
Provexis has developed Fruitflow, a patented extract from tomato that has been proven to inhibit blood platelet aggregation, thereby reducing the risk of thrombosis. A thrombosis is an aberrant blood clot that can lead to heart attack and stroke. Provexis has integrated Fruitflow into a fruit juice beverage called Sirco. When launched - initially in the United Kingdom - it will be the first functional food carrying the claim Helps maintain a healthy heart and benefit circulation with a measurable benefit within hours of consumption.

Provexis is developing a proprietary extract from a special breed of broccoli (non-GMO) which is enriched in compounds known to reduce the risk of specific cancers. Provexis intends to use this food-derived bioactive to underpin a new range of functional beverages with scientifically proven protective properties.

In addition, Provexis is developing a patented extract from plantain with a view to developing a novel medical food for the dietary management of Inflammatory Bowel Disease, specifically Crohns Disease in the first instance.

another kick up for pxs. again this wasnt flagged up by the news ticker!!

"Provexis PLC
12 September 2005


PROVEXIS PLC
('Provexis' or the 'Company')

COLLABORATION AGREEMENT FOR CROHN'S DISEASE TECHNOLOGY

Exercise of right to assign intellectual property from University of Liverpool


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to announce that it has entered into
a collaboration agreement with a leading clinical nutrition company ('the
Company').

Provexis is currently developing a proprietary bioactive extract from the
Plantain (part of the banana family) which is designed to extend remission in
patients suffering from Inflammatory Bowel Disease (IBD). IBD has two forms,
Crohn's Disease and Ulcerative Colitis, both are chronic inflammatory diseases
of the digestive tract which, combined, affect approximately 1 in 400 in the
western world countries.

Under the terms of the collaboration agreement, Provexis and the Company will
develop a medical food product incorporating this bioactive extract. It is
intended that the food product will enter clinical trials in 2006 on patients
suffering from Crohn's disease. Crohn's Disease is currently incurable with the
primary goals of treatment being control of the inflammation, the relief of
symptoms, addressing nutritional deficiencies and the extension of remission
time.

The Company will be responsible for the formulation, manufacture and packaging
of the medical food product to be used in the full clinical trial and will have
the option of securing an exclusive negotiation period after the trial. The
negotiation period would give the Company the rights to be the first company to
pursue the manufacturing and distribution rights for the product. However,
Provexis is not obliged to enter into an agreement with the Company for these
rights and furthermore, all intellectual property, including the industrial
formulation of the medical food product, is wholly-owned by Provexis.

In addition, following successful pre-clinical studies on this medical food
treatment by the University of Liverpool and Provexis, Provexis has exercised
its right to the assignment of the intellectual property from the University of
Liverpool to a new Provexis subsidiary in which the University will be a
minority shareholder.

The specific components in Plantain with this therapeutic potential were
discovered by Professor Jon Rhodes, based in the Department of Medicine at the
University of Liverpool and an Honorary Consultant Gastroenterologist at the
Royal Liverpool University Hospital.

Dr Stephen Franklin, CEO of Provexis, commented: 'This is another significant
milestone in the development of Provexis. This collaboration is an important
validation of the strength of the Provexis technology pipeline.'


Ends


For further information please contact:

Provexis plc
Dr Stephen Franklin, CEO 07710 348 774

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232


Notes to Editors

Provexis develops scientifically proven functional and medical foods. Functional
foods are foods such as Benecol and Flora pro.activ that contain physiologically
active food components and provide health benefits beyond basic nutrition.
Medical foods are administered to patients by a physician for the dietary
management of specific diseases.

In June 2005 the Company joined AIM via a reverse takeover by Nutrinnovator.
Nutrinnovator brings with it a technology pipeline as well as marketing, selling
and business development skills.

Provexis was formed in December 1999 by the life-science subsidiary of the
venture-management company, ANGLE plc. In January 2000, Provexis entered into a
new technology option agreement with Rowett Research Services Ltd. (RRS), the
commercial subsidiary of the Aberdeen based Rowett Institute, and this option
was exercised in November 2001. Provexis' agreements with RRS have provided it
with the intellectual property rights pertaining to its lead product, Fruitflow.
Provexis continues to have strong links with the Rowett Institute, which
provides the company with R&D facilities, human trials and, potentially, new
technologies.


IBD - Technical

Researchers at the University of Liverpool have recognised that IBD may
represent an altered response to normal intestinal microbes In particular, they
believe there is a possibility that apparently non-pathogenic 'harmless '
bacteria can cause inflammation if they penetrate the intestinal mucus and
associate themselves with the lining cells of the intestine.

The researchers have characterised the adherence of Inflammatory Bowel Disease
related bacteria to carbohydrate structures on the lining of the intestine and
found that the adhesion of such bacteria to cell surfaces can be blocked by
some, but not all, complex carbohydrates. In particular, they found that
specific types of soluble fibre, extracted from Plantain, were particularly
effective for preventing bacterial adhesion and accordingly may have efficacy
for preventing or treating IBD. They believe that the soluble fibres may either
mimic or compete with bacterial receptors, thus preventing bacterial recruitment
and subsequent inflammation.

This discovery has led Provexis to believe that a Plantain--based formulation
(as developed by chemists at Provexis and tested at the University of Liverpool)
could underpin a new medical food treatment for extending remission time in
patients with IBD.

The medical food product is anticipated to enter a two-site clinical trial on
patients with Crohn's Disease in Summer 2006.



This information is provided by RNS
The company news service from the London Stock Exchange

just seen this on the psg thread. hope sd doesn't mind. taken from a post from feb 2005.

"Peter Brabeck, head of Nestle and one of the most influential
people in the food industry, was interviewed in yesterdays Financial
Times:-

"It is my conviction that the next value creation, and it will be huge,
is going to be nutritional aspects. That is what allows you to ask 40%
more for your products".

The article continued that foods with medical benefits, otherwise known
as functional foods or nutraceuticals are expected to be the big source of
growth for the next 15 to 20 years. "

all gone a bit quiet and the sp has dropped a touch. not really much going to happen until january , i think.

looks like pxs have decided to ditch altu. makes sense as it was loss making.

Provexis PLC
05 October 2005


PROVEXIS PLC

Disposal of Altu

Provexis plc ('Provexis' or the 'Company') AIM: PXS.L, announces the sale of its
Altu food business to Go Lower Limited for a cash consideration of 75,000 which
will be used for working capital purposes.

As stated at the AGM, the Board has been closely monitoring the performance of
Altu. The brand has recently extended its distribution, via a new pack format,
in two multiple grocers, and continues to enjoy national distribution in High
Street and Major Multiple Grocers. However, following a strategic review, the
Board has concluded that, in order to focus on the core activity of functional
foods, a disposal of the Altu business is in the best interests of the Company
and shareholders.

For the year ended 31 March 2005, the Altu business was loss-making, after
direct overheads on turnover of 298,000 and in the year to date has continued
to be loss-making. The disposal therefore will have a cash positive effect on
Provexis' business going forward.

Commenting, Dr Stephen Franklin, CEO said:

'Provexis will now be able to focus its resources and management time on its
core business: the development of novel, patented, food bioactives with
scientifically-proven health benefits. These will be commercialised via a
combination of licensing and own-brand functional foods.'

3 November 2005

PROVEXIS PLC
('Provexis' or the 'Company')


US PATENT AWARDED COVERING FRUITFLOW TECHNOLOGY


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces that it has received a patent grant from
the United States Patent Office covering its FruitflowTM technology.

The FruitflowTM technology covered by this patent was discovered at the Rowett
Research Institute in 1998 and has been developed and clinically tested by
Provexis since 2000. FruitflowTM contains a bioactive extract from tomatoes
which has been proven in human trials to inhibit blood platelet aggregation and
thereby reduce the risk of thrombosis, a primary cause of heart attack and
stroke. The technology already has patent protection in Europe, granted in July
2003, and in Australia, granted in August 2004. It is also anticipated that
patent protection will be granted in Japan, Mexico and Canada in the near
future.

Provexis will be launching the FruitflowTM technology in its lead product, the
fruit juice drink SircoTM, in January 2006 in the UK. SircoTM has been approved
by HEART UK and will carry the claim 'helps to maintain a healthy heart and
benefits the circulation'. SircoTM is differentiated from existing cholesterol
management products in that the benefit is associated with blood thinning and is
effective from the first serving. The launch will be targeting a new, emerging
category in the functional food market in the UK: heart-healthy functional
juices. The market for heart-healthy foods worldwide is expected to reach US$4.6
billion of sales by the end of 2005.

Dr Stephen Franklin, Chief Executive Officer of Provexis, said: 'We are
delighted to have been granted the US patent for our FruitflowTM technology. We
now have patent protection in our two largest target markets, the United States
and Europe. This is a critical development in terms of our licensing ambitions
and it means that we can start to make significant in-roads into the US
functional food market, which is expected to reach US$34 billion of sales by
2010.'


this is fantastic news for pxs!!!

wheres this one going fruit flow released to market january ,going to get some haVe a taste .they haVe had 2 jumps off 5p will they brake this range to find 10p and aboVe ,they were 60p without there patent or product tomarket .i hold 50k shares at 6.4p ,thinking to double up on next dip haVe a good feeling about these ,

more news today.

Provexis PLC
07 November 2005



7 November 2005



PROVEXIS PLC
('Provexis' or the 'Company')


Provexis plc is awarded Research Grant for Crohn's Disease Technology from North
West Development Agency


Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to announce that it has been awarded
a research grant for its Crohn's disease technology from the North West
Development Agency. The grant is for 180,000 and will assist the funding of the
Company's development of its novel, medical food for the treatment and dietary
management of inflammatory bowel disease (IBD).

Provexis is currently developing a proprietary bioactive extract from plantain
(part of the banana family) which is designed to extend remission in patients
suffering from IBD, which exists in two forms - Crohn's disease and ulcerative
colitis. Collectively, both forms of the disease affect approximately 1 in 400
in the western world. According to Decision Resources (2004), for Crohn's
disease alone, the therapeutic market across the seven major countries in the
world was estimated at 1bn in 2003 with new technologies expected to be the
driver behind significant growth.

The proposed medical food contains a patented natural source of soluble fibre
extracted from the plantain. If successful, it will be the first medical food
which involves treatment of the actual inflammation associated with the disease,
unlike existing medical food treatments which only address nutrient
insufficiencies and imbalances in IBD sufferers.

Provexis had previously secured financial support for this project from the DTI
in 2004 with a 45,000 DTI SMART Feasibility Award.

The award from the North West Development Agency was won following a competitive
pitch which involved rigorous analysis of the Company's technology, intellectual
property and commercial capability by a team of independent referees.

Commenting on the grant, Provexis' Chief Executive, Dr Stephen Franklin, said:
'We are delighted to receive this substantial grant from the North West
Development Agency. Given the strength of the competition in bidding for this
award, it is a clear testament to the quality of the technology we are
developing, the robustness of the intellectual property and the scale of the
commercial opportunity. Crohn's Disease remains an area of significant unmet
clinical need in a therapeutic market that now exceeds 1bn. This grant enables
us to extend the scale of the clinical trial which commences next year.'

results

Provexis PLC
16 December 2005




PROVEXIS PLC
('Provexis' or the 'Company')

UK Launch of Sirco(TM)

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, is delighted to confirm the launch of its
Sirco(TM) heart health juice drink in the UK in January 2006.

The Company has so far secured an initial distribution base with two of the five
largest supermarket retailers in the UK, which for reasons of commercial
confidentiality cannot be named at present. Both retailers will distribute
Sirco(TM) nationally. Within the larger of the two supermarket groups, Sirco(TM)
will be initially available in premier stores which represent, by weighted
distribution, approximately 35 per cent. of their total UK distribution base.
Within the second supermarket chain, Sirco(TM) will be initially available, by
weighted distribution, across 70 per cent. of their total UK distribution base.
Both retailers will stock Sirco(TM) in one litre packs of both flavour variants,
Apple & Blueberry and Orange, and the drink will be located in the chilled fruit
juice section.

The Company is in on-going discussions with a number of other retailers and
hopes to make further distribution announcements in 2006. In addition to the one
litre packs, the Company is also developing a 250ml bottle of Sirco(TM) for
distribution to retailers in mid 2006. This bottle will have an extended shelf
life and is intended to widen the distribution base to include independent
chemists, convenience stores and food service industry channels such as health,
education and travel outlets.

Sirco(TM) is the first heart health product to contain the patented
Fruitflow(TM) technology. Fruitflow(TM) was developed by Provexis in order to
help regular 'healthy' consumers reduce the risk of heart attack and stroke. The
natural bioactive works by reducing blood platelet aggregation ('thinning the
blood'), a significant contributing factor to a thrombosis (internal blood
clot). Sirco(TM) carries the health claim 'Helps to Maintain a Healthy Heart and
Benefits Circulation' and is approved by the leading heart health charity, HEART
UK.

Commenting on the forthcoming launch Dr Stephen Franklin, CEO of Provexis, said:

'This marks a significant milestone for Provexis and we are delighted that we
have secured distribution with two of the largest UK supermarkets. Both
retailers are ideal outlets in terms of the demographics and target market for
this product. We will be investing in media advertising as well as in-store
activity to ensure we maximise this substantial opportunity.

We look forward to growing the retailer base for Sirco(TM) throughout 2006,
whilst in parallel securing licensing arrangements with major international food
partners to integrate the FruitFlow(TM) technology into new food products in
global markets.'



good news!!

yes good news on the shelVes january and adVerts planed to get attention ,bought back in after takeing profit about month ago, in lower aVarage 6.1 better than last time got it right for this one. we should see more gains next week now supermarkets are onboard.

up 11% would like to know what is posible income from fruit flow ,these should keep on riseing lot of Volume today.

cellby
15m sells yet your up 11% ?

driVer not sure that was all selling ,may haVe been sum orders filled from friday or first thing today . it was nearly certain to go up today with news from friday product on shelVes 2 super market chains and more to come ,its out of the deVelopment pan into the sales fire.could be some big profit takeing if we hit 8p including me.may be a return tomorrow about all these million of shares moVeing home.

x-trades thread

i know today's sells are not x trades, but it may be the same explanation for the rise.

STRONG BUY

who from ,sold half of mine yesterday 15% profit on day trade ,thought might get them back on the drop ,didnot get there 6.4 my buy back may not see it.

From me - nice strength shown today intra-day, relatively low sell volumes today, most people in for the launch. Think this will rise for the last 2 days of the week and possibly form a new high.

From the company secretary.

Sirco will be available in Sainsburys from the second week in January in the chilled juice section, and will be available in Waitrose stores from 25th January. Unfortunately, at this stage I am not able to tell you which stores, until the retailers confirm this information with us.

Provexis PLC
09 January 2006


9 January 2006

PROVEXIS PLC
('Provexis' or the 'Company')

Further Major Distribution Agreement for SircoTM

Provexis, the nutraceutical company that develops scientifically-proven
functional and medical foods, announces a further distribution agreement with a
market leading supermarket chain for its SircoTM heart health juice drink.

From February 2006, SircoTM Blueberry & Apple variety will be stocked in
approximately 200 of this supermarket's key premier stores bringing the total UK
distribution base for SircoTM to over 500 stores by the end of February 2006.

Further to the Company's announcement released on 16 December 2005, SircoTM is
now available in 211 Sainsbury's stores and is expected to be available in 100
stores of the second multiple supermarket chain from 23 January 2006.

SircoTM is the first heart health product to contain the patented FruitflowTM
technology. FruitflowTM was developed by Provexis in order to help regular
'healthy' consumers reduce the risk of heart attack and stroke. The natural
bioactive works by reducing blood platelet aggregation ('thinning the blood'),
a significant contributing factor to a thrombosis (internal blood clot). SircoTM
carries the health claim 'Helps to Maintain a Healthy Heart and Benefits
Circulation' and is approved by the leading heart health charity, HEART UK.

Commenting on the expanded distribution, Dr Stephen Franklin, CEO of Provexis,
said:

'We are delighted to have secured a listing with a third major retailer. The
distribution base of SircoTM is expanding on schedule and will be sufficiently
established to maximise the nationwide, multimedia, advertising campaign which
will run throughout the Spring and early Summer'.

For further information please contact:

Provexis plc
Dr Stephen Franklin 020 8392 6631

Bell Pottinger Corporate & Financial
Ann-Marie Wilkinson/Emma Kent 020 7861 3232

looks like everything is going to plan.

Provexis PLC
17 January 2006


PROVEXIS PLC ('the Company')

17 January 2006

DIRECTORS' DEALINGS

On 16 January 2006, the Board of Provexis plc approved the grant to Directors of
options over ordinary shares in the Company under the Company's 2005 Share
Option Scheme, exercisable at 8.62p per share, any time between 3 and 10 years
of the date of grant, as follows:

Director Options granted Total Options held following Grant

Stewart Slade 2,088,167 2,088,167

The options are exercisable between 3 and 10 years from grant.